Effects of Prior Exposure to Conflicting Health Information on Responses to Subsequent Unrelated Health Messages
9 novembre 2020 mis à jour par: University of Minnesota
Many population-level public health strategies-including media campaigns and other behavioral interventions, screening recommendations, and vaccination policies-rely on messaging to promote cancer prevention and control.
These strategies do not take place in a vacuum; rather, they occur in the context of a broader public information environment, which is increasingly characterized by conflicting and often controversial health information.
Although studies have documented that such information is prevalent, a critical question remains unanswered: does exposure to conflicting health information in people's routine interactions with the broader information environment threaten the success of message-based population-level public health strategies?
And, if so, who is most susceptible to the effects of such exposure?
This study will provide a rigorous empirical test of these critical answered questions, guided by two specific aims: First, to evaluate whether prior exposure to conflicting health information influences responses to subsequent unrelated and uncontested health messages, a phenomenon that has been described as "carryover effects" (Primary Aim); and second, to identify whether there are individual-level differences in how conflict affects responses to these unrelated and uncontested health messages (Secondary Aim).
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
To accomplish these aims, an online survey-based experiment using a population-based sample of U.S. adults (anticipated N=1,800) will be conducted.
At 2 time points across a 28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding.
Participants will be randomized to 1 of 2 treatment groups that differ only in the amount of conflict presented in these news and social media posts (conflict, no conflict).
At a third time point, after the exposure to conflict period, all participants will be exposed to 3 (out of a possible 9) messages from existing health campaigns about 3 behaviors for which there is scientific consensus: fruit and vegetable consumption, colorectal cancer screening, and physical activity.
To assess carryover effects (Primary Aim), participants' receptivity to these messages-as measured through several affective and cognitive responses (e.g., confidence in the evidence presented)-will be measured.
Message receptivity is expected to be lower among those who were randomized to receive conflicting health information.
Individual-level differences in message receptivity are possible; thus exploratory analyses (Secondary Aim) will be conducted to assess whether carryover effects of exposure to conflict may be more pronounced among certain groups (e.g., those with greater trust in media sources, those of lower socioeconomic position).
Type d'étude
Interventionnel
Inscription (Réel)
6046
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60603
- NORC at the University of Chicago (online only)
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Oui
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- 18+ U.S. adults
- Members of NORC's AmeriSpeak Panel (https://amerispeak.norc.org/Pages/default.aspx)
- Able to complete web-based survey
- Able to read in English
Exclusion Criteria:
- None
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: No exposure to conflict
|
At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding.
Participants in the no conflict (comparator) group will have no conflicting information included in these news and social media posts.
|
|
Expérimental: Exposure to conflict
|
At 2 time points across a ~28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding.
Participants in the conflict (experimental) group will have conflicting information added to these news and social media posts.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Negative affective responses
Délai: Up to 42 days
|
|
Up to 42 days
|
|
Counterarguing
Délai: Up to 42 days
|
• Participants are asked to indicate the extent to which they agree or disagree with 4 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):
|
Up to 42 days
|
|
Reactance/threat to freedom
Délai: Up to 42 days
|
• Participants are asked to indicate the extent to which they agree or disagree with the following statement (response options: 1 "strongly disagree" to 5 "strongly agree"): "I felt like the ad was trying to manipulate me"
|
Up to 42 days
|
|
Other negative cognitive responses to ad claims
Délai: Up to 42 days
|
• Participants are asked to indicate whether "the claims in the ad I just saw are" (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"): exaggerated, flawed, believable (reverse coded), reasonable (reverse coded)
|
Up to 42 days
|
|
Perceived argument strength
Délai: Up to 42 days
|
• Participants are asked to indicate the extent to which they agree or disagree with 2 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):
|
Up to 42 days
|
|
Response efficacy
Délai: Up to 42 days
|
• Participants are asked to respond to two items, presented in random order:
|
Up to 42 days
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
20 juillet 2020
Achèvement primaire (Réel)
31 août 2020
Achèvement de l'étude (Réel)
31 août 2020
Dates d'inscription aux études
Première soumission
16 janvier 2020
Première soumission répondant aux critères de contrôle qualité
27 janvier 2020
Première publication (Réel)
30 janvier 2020
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
10 novembre 2020
Dernière mise à jour soumise répondant aux critères de contrôle qualité
9 novembre 2020
Dernière vérification
1 novembre 2020
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 2019NTLS140
- R21CA218054 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
INDÉCIS
Description du régime IPD
Within one year of study completion, the final, cleaned, de-identified study dataset may be made available to third-party users under a data-sharing agreement that provides for: 1) a commitment to using the data only for research purposes; 2) a commitment to securing the data using appropriate information technology; and 3) a commitment to destroying or returning the data after analyses are completed.
Requests for data sharing will be considered by the investigator team via in-person meetings and approved by consensus; meeting minutes will be taken to ensure transparent decision making and conflict of interest avoidance.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .